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Genome-Wide Analyses Demonstrate Novel Loci That
Predispose to Drusen Formation
Gyungah Jun,1 Barbara E. K. Klein,2 Ronald Klein,2 Katherine Fox,1 Christopher Millard,1
Jennifer Capriotti,1 Karlie Russo,1 Kristine E. Lee,2 Robert C. Elston,1 and
Sudha K. Iyengar1,3
PURPOSE. To test whether genes for drusen formation are inde-
pendent of age-related macular degeneration (AMD) pathogen-
esis.
METHODS. A genome-wide model-free linkage analysis was per-
formed, using two semiquantitative drusen traits, size and type,
on two sets of data: (1) 325 individuals (225 sib pairs) from the
Beaver Dam Eye Study (BDES), and (2) 297 individuals (346 sib
pairs) from the Family Age Related Maculopathy Study
(FARMS). Apolipoprotein E (APOE) genotypes were used as a
covariate in a multipoint sibpair analysis.
RESULTS. The authors found evidence of linkage on 19q13.31
(D19S245), with size of drusen in both the BDES (P  0.0287)
and the FARMS (P  0.0013; P  0.0005, combined). In the
BDES, type showed linkage evidence on 3p24.3 (D3S1768;
P  0.0189) and 3q25.1 (D3S2404; P  0.0141); the linkage
on 3p24.3 was also found with size (D3S1768; P  0.0264). In
the FARMS, size showed evidence of linkage at 5q33.3
(D5S820; P  0.0021), 14q32.33 (D14S1007; P  0.0013), and
16p13.13 (D16S2616; P  0.0015) and type at 21q21.2
(D21S2052; P  0.0070). For size in the FARMS, there was a
small increase in P-value at marker D19S245 from 0.0044 to
0.0111, and from 0.0044 to 0.0064, when the 4-carrier and
the 3-carrier genotype were the covariates, respectively.
CONCLUSIONS. The results show that APOE effects may be me-
diated early in the progression of ARM to AMD and thus may
not be detected by standard genome scans for more severe
disease. (Invest Ophthalmol Vis Sci. 2005;46:3081–3088) DOI:
10.1167/iovs.04-1360
Age-related maculopathy (ARM) is a complex degenerativeeye disorder that primarily affects the macular region of
the eye. Progression from ARM to age-related macular degen-
eration (AMD) is the main cause of blindness in the elderly
population in the United States. Approximately 1.7 million
Americans 40 years of age or older have the advanced stages
and 7.3 million show the earlier stages of AMD.1–3 Despite
extensive research on AMD, the effect of drusen formation on
AMD pathogenesis remains unknown. One assumption in this
process is that drusen represent an early stage in the natural
history of disease and that other genes are necessary for the
progression to exudative or neovascular stages of the disease.
Hamdi and Kenney4 proposed that drusen formation is inde-
pendently controlled by genes affecting many retinal dystro-
phies, citing as examples the presence of drusen in other
retinal dystrophies such as RDS-associated pattern dystrophy,
Stargardt disease, dominant drusen dystrophy, glomerulone-
phritis type II, and North Carolina macular dystrophy. They
also proposed that progression to advanced neovascular stages
of AMD invokes separate genetic pathways.
So far, six genes have been associated with AMD. They
include the ATP-binding cassette rim protein (ABCA4),5,6
apolipoprotein E (APOE),7,8 angiotensin converting enzyme
(ACE),9 complement factor H (CFH),10 –12 hemicentin-1,13
and fibulin 5 (FBLN5).14 Of these genes, APOE is an attrac-
tive candidate for AMD pathogenesis. A recent study showed
that the APOE protein is present in the human retina and the
retinal pigment epithelium (RPE),15 and age-related alter-
ation of lipoprotein biosynthesis at the level of the RPE
and/or Bruch’s membrane may be a significant contributing
factor in drusen formation and AMD pathogenesis.16 Genetic
association between AMD and the APOE gene has been
observed in mouse models,17,18 as well as in human case–
control studies,7,8,19 –21 although this association has not
been observed in all studies.22 In those studies in which this
association was observed, the APOE epsilon 4(4) variant
had a protective effect and the epsilon 2(2) variant dis-
played an increased risk for AMD.
To test whether genes that promote drusen formation are
independent of AMD pathogenesis, we conducted genome
scans on two separate phenotypes: maximum drusen size and
severe drusen type. We used data from two different cohorts,
the Beaver Dam Eye Study (BDES) and the Family Age Related
Maculopathy Study (FARMS), to test this hypothesis. The BDES
has families with all grades of ARM severity, from early to late,
and has previously been analyzed for the genetics of ARM.23
The FARMS data set includes families ascertained through pro-
bands with severe AMD, and a genome scan for AMD has also
been conducted.24 We compared the results obtained from our
previous scans of maculopathy with those of drusen compo-
nents to identify novel and shared candidate regions.
METHODS
Subjects
The study population consisted of two cohorts: the BDES and
FARMS. The BDES includes a community sample of 4926 subjects
between 43 and 86 (average, 65.13) years of age at baseline, and a
detailed description of this cohort is given elsewhere.23 In brief,
2783 subjects in 602 pedigrees were collected from initial screen-
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ing. From these, 105 sibships were selected for genotyping and
linkage analysis.
The FARMS data were ascertained through index cases with ad-
vanced AMD with 306 individuals in 34 families between 20 and 90
(average, 62.81) years of age recruited from the Retinal Clinic at the
University of Wisconsin.24 The Internal Review Boards at the Univer-
sity of Wisconsin and Case Western Reserve University approved these
studies, and informed consent was obtained from all participants. The
research was performed in accordance with the principles of the
Declaration of Helsinki.
Phenotypic Evaluation
The size and type of drusen were judged according to the Wisconsin
Age-Related Maculopathy Grading Scheme, the detailed description of
which is found elsewhere.25 For each eye a severity score was assigned
to each drusen size category phenotype as follows: none  0, ques-
tionable  1, 63 m in diameter  2, 63 m to 125 m in
diameter  3, 125 to 250 m in diameter  4, 250 m in
diameter  5, and reticular drusen  6. Similarly, a severity score was
assigned for each drusen type category phenotype as follows: none or
hard indistinct  0, hard distinct  1, soft distinct  2, and soft
indistinct or reticular  3.26
For each phenotype, measurements for the right and left eyes were
averaged at each time point. However, if a score was missing for either
eye, then the score for the available eye was substituted for the missing
score. Overall, substitution occurred 6.45% of the time for size (n 
2308) and 13.03% for type (n  2288) in the BDES and 5.63% for size
(n  284) and 18.98% for type (n  274) in the FARMS. The BDES
cohort had data that were collected at 5-year intervals for up to three
time points. To include the same or a similar amount of information on
each individual, the mean scores of the right and left eyes were
averaged separately for size and type over two time points whenever
possible. When scores at all three time points were available, the first
and last mean scores were averaged; otherwise, the mean scores at the
two available time points were averaged. At least two time points of
measurements were available for size and type in 75.23% and 74.48%
of participants, respectively.
We used multiple regression models to examine the effects
of gender, age (at baseline for the BDES), history of heavy drinking,
and history of smoking, along with the first-order interactions of
these effects, assuming independence of all observations. In the
BDES, we found age, age2, history of heavy drinking, interaction
between age and history of heavy drinking, and interaction between
history of heavy drinking and history of smoking, to be nominally
significant at the 5% level in predicting drusen size. Drusen type was
predicted by age, age2, and interaction between age and history of
smoking. In contrast, for the FARMS, both size and type were
predicted solely by age and age2.
To minimize the variance among individuals due to age differences,
we used the regression model from the previous section. First, we
calculated the residuals for each observation from the final regression
model. Next, we obtained the predicted value for an individual at age
80 from the final model. Finally, we added the residuals to this pre-
dicted value to obtain our final phenotypes.
Genotyping and Error Checking
After extracting DNA from the blood samples, we used a fluorescence-
based genotyping method for the genome scan.23,24 We genotyped 351
markers on 22 chromosomes using the Weber panel 8 marker set in the
BDES, which has an average marker spacing of 11 cM. In addition, we
included markers in fine-mapped regions of chromosomes 3, 5, 12, and
16 from our previous genome scan.23 Our analysis included extended
coverage of additional fine-mapped regions, which consisted of 25, 8,
10, and 4 markers on chromosomes 3, 5, 12, and 16, respectively. We
also genotyped individuals from 34 extended families in the FARMS
with 381 markers on 22 autosomes, by using the Weber panel 10 of
microsatellite markers. This covered the genome at an average marker
spacing of 8.85 cM. Two additional markers, D1S406 and D1S236, in
close proximity to the ABCA4 gene, were also genotyped. We also
included 4, 25, and 14 markers on chromosomes 1, 12, and 15,
respectively, from our previous study.24 As a result, the average inter-
marker distance of fine-mapped regions on chromosomes 1, 12, and 15
decreased to 3.13, 3.40, and 2.86 cM, respectively. Approximately 77%
of the markers were shared between the two screening sets.
On the basis of the initial findings from the genome scans, APOE
was selected to be genotyped. APOE genotyping was performed by
using the previously described restriction endonuclease (HhaI)
method followed by agarose electrophoresis.27 We included all the
individuals who were originally genotyped (n  325 in the BDES; n 
297 in the FARMS). Seven individuals from FARMS were set to “miss-
ing” in subsequent covariate analysis, because their genotypes were
not available.
Inconsistencies of the genotypes within families were examined
using MARKERINFO in S.A.G.E. (ver. 4.5; available at http://darwin.cwru.
edu/sage/, provided by the Case Western University, Cleveland, OH). In
total, 0.69% and 0.24% of the data were treated as missing in the BDES and
the FARMS, respectively. In addition, we checked misclassification of
relationships in each pedigree using RELTEST in S.A.G.E. (ver. 4.5). In the
BDES, we reclassified 6 individuals in 3 full sibships as unrelated and 21
individuals in 12 full sibships as half-sibs.23 In the FARMS, we cleaned
genotyping errors, as well as reclassified four individuals in four full
sibships as half sibs, and deleted three individuals in three full sibships
because they were unrelated.24
Linkage Analyses
To perform a Box-Cox power transformation of the data to maximize
power, we performed segregation analysis with SEGREG in S.A.G.E.
(ver. 4.5) on these values from the entire BDES sample (size: N  2308;
type: N  2288) to obtain appropriate population-based transforma-
tion parameters. Before transforming the phenotypes in both the BDES
and the FARMS, we examined the correlations between size and type.
Size and type correlate highly in both the BDES (0.875) and FARMS
(0.862). Transformation of the data with the power parameter 1 
1.45 for both size and type obtained from the population-based study
(BDES) led to retention of the original correlation structure of 0.874 in
the BDES and 0.857 in the FARMS. Since the population-based param-
eter altered the correlation little between size and type after transfor-
mation, subsequent analyses were conducted by using this transforma-
tion. We also checked the correlations between drusen phenotypes
and 15-step AMD severity scale (AMD score).23
Sibling correlations for the size and type were estimated using the
FCOR program in S.A.G.E. (ver. 4.5). We performed linkage analyses
on the power transformed size and type phenotypes, separately in the
BDES and the FARMS, using the GENIBD and SIBPAL programs in
S.A.G.E. (ver. 4.5). A weighted combination of squared trait difference
and squared mean-corrected trait sum (W4 option) was used as the
dependent variable in a Haseman-Elston regression model.28,29
In regions where both the BDES and the FARMS showed linkage,
we combined the P-values of the two independent tests, using the
Fisher method: letting P1 and P2 be the two P-values, 2¥i1
p Ln(Pi) is
compared with the 2 distribution with four degrees of freedom.30
Candidate Gene Covariate Analysis
We coded the APOE alleles in two different ways: First, for the additive
model, we counted the number of a specific allele, and coded an
individual as having 0, 1, or 2 alleles of that type. Second, for the
dominant model, we ascertained the presence of a certain allele (e.g.,
2) and coded for its absence or presence as 0 or 1, without regard for
homozygosity or heterozygosity for that allele. For example, the three
different genotypes 2/3, 3/3, and 3/4 share the same value
(code  1) in the 3 dominant model (E3Dom), but in the 3 additive
model (E3Add) they were coded as 1, 2, and 1, respectively. We
performed model-free linkage analysis with the newly derived covari-
ate included in the model to determine whether inclusion of the
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covariate (APOE genotype) eliminates the observed linkage in this
region on chromosome 19. We compared each covariate model with
the baseline model (no covariate).
RESULTS
Description of Phenotypes
The BDES and FARMS data sets included 325 and 290 geno-
typed individuals with available phenotypes, respectively. We
found larger sized drusen (250 m in diameter or reticular)
in the FARMS (15.17%) than in the BDES (5.54%). For type, the
number of individuals with soft drusen (distinct or indistinct/
reticular) was higher in the BDES (49.54%) than in the FARMS
(37.93%). We observed that both drusen size and type corre-
lated highly with the AMD score. The correlations between
drusen phenotypes (size and type) and the AMD score in the
BDES are 0.8192 and 0.8215 for the size and type, respectively;
in the FARMS, 0.7310 and 0.7458 for the size and type, respec-
tively. Table 1 summarizes the phenotypic description in the
BDES and FARMS.
Genome Scan
The BDES data set consisted of 225 sib pairs with size and 224
sib pairs with type, available in 105 families; the FARMS data
set comprised 346 sib pairs with both size and type measures
available. The correlations between siblings for size and type
were 0.1760 and 0.2174 in the BDES, respectively; 0.1074 and
0.0858 in the FARMS, respectively. In addition, the sibling
correlations between size and type in the BDES and the FARMS
were 0.1961 and 0.1043, respectively. The result of the ge-
nome scans for the BDES and the FARMS are presented in
Figures 1 and 2, respectively. In addition, Table 2 displays
markers that had a nominal multipoint significance level of P 
0.01 in either study. In the FARMS, we found linkage for size at
five markers on chromosomes 5, 14, 16, and 19, and for type at
one marker on chromosome 21 (Table 2). In the BDES, al-
though we did not detect regions with a nominal significance
level of P  0.01, we observed the shared regions on chromo-
somes 3 and 19, for both size and type, with a nominal signif-
icance level of P  0.05 (Table 3).
The region with the highest linkage peak was found on
chromosome 19 (19q13.31), for drusen size, in the FARMS (Fig.
2), and there was a similar but weaker peak in the BDES (Fig.
1). The location of the linkage peak was near D19S245 in the
FARMS (46 cM; P  0.0013) and in the BDES (50 cM; P 
0.0243), and the combined P-value for the two data sets is
0.0005.
We observed additional linkage signals in the FARMS (Fig. 2;
Table 2) on three chromosomes (5q33.3, 14q32.33, and
16p13.13) with size. We detected two closely located peaks on
chromosome 5 near D5S816 (138 cM; P  0.0204) and at
D5S820 (160 cM; P  0.0021). The linkage evidence on chro-
mosome 14 was seen near the long arm at D14S1007 (126 cM;
P  0.0013). On chromosome 16, the signal was seen at
D16S2616 (11 cM; P  0.0015). With type, we observed a
linkage signal on chromosome 21 at D21S2052 (22 cM; P 
0.0070).
In addition, we found interesting regions on chromosome 3
(3p24.3 and 3q25.1) in the BDES that showed similar linkage
signals with size and type (Fig. 1; Table 3). At D3S1768 on
chromosome 3, we found a linkage signal with both size (55.98
cM; P  0.0264) and type (60 cM; P  0.0189). The second
signal on chromosome 3 near D3S2404 (166 cM) illustrated
evidence of linkage with type (P  0.0141).
Covariate Analysis with APOE Alleles
We chose to follow up the region on chromosome 19 be-
cause this chromosome gave the most significant results and
the APOE gene lies within the 1-lod decrease in significance
interval. Moreover, previous association studies suggested
APOE alleles are associated with AMD.7,8,19 –21 Overall the
APOE genotype and allele frequency distributions in the
BDES and FARMS are shown in Table 4. The most frequent
genotype was 3/3, both in the BDES (59.38%) and the
FARMS (54.48%).
A summary of the findings in the BDES and FARMS with
APOE genotype as a covariate is shown in Table 5. Inclusion
of APOE as a covariate in linkage models led to a decrease in
linkage signals compared with baseline (i.e., without a co-
variate). The P-value at marker D19S245 in the FARMS was
increased by approximately one order of magnitude from
TABLE 1. Phenotypic Description of Genotyped Individuals in the BDES and the FARMS
Average
Severity Scale*
BDES (n  325) FARMS (n  290)
Total (%) AMD (SD)† Total (%) AMD (SD)†
Drusen size
Missing‡ 1 (0.31) — 10† (3.45) —
0 1 (0.31) 1 (0.00) 10 (3.45) 3.64 (5.59)
0 to 1 16 (4.92) 1.22 (0.31) 34 (11.72) 2.54 (3.74)
1 to 2 115 (35.38) 2.43 (0.51) 94 (32.41) 2.89 (2.51)
2 to 3 114 (35.08) 4.21 (1.41) 63 (21.72) 4.73 (2.78)
3 to 4 60 (18.46) 6.91 (2.18) 35 (12.07) 9.16 (3.87)
4 to 5 17 (5.23) 10.31 (1.86) 39 (13.45) 11.71 (2.14)
5 1 (0.31) 10 (0.00) 5 (1.72) 11.6 (1.98)
Drusen type
Missing‡ 2 (0.62) — 20 (6.90) —
0 8 (2.46) 1 (0.00) 12 (4.14) 3.17 (5.06)
0 to 1 154 (47.38) 2.60 (0.71) 148 (51.03) 3.04 (2.50)
1 to 2 114 (35.08) 4.91 (1.89) 52 (17.93) 6.71 (3.98)
2 47 (14.46) 8.72 (2.24) 58 (20.00) 11.30 (2.50)
* Scales were calculated by averaging left and right eye.
† The 15-scale AMD severity score was averaged over individuals in the same category.
‡ Missing  inability to grade; see Methods section for additional details of phenotype.
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0.0044 to 0.0111 with the presence of 4 (E4Dom), but did
not change much (from 0.0044 to 0.0064) with the presence
of 3 (E3Dom). However, the linkage signal did not entirely
disappear, even after the APOE alleles were accounted for.
This implies that the linkage peak on chromosome 19 is not
fully accounted by the APOE gene, and a novel locus, close
to APOE, may be additionally associated with large soft
drusen. We did not find the same covariate effect in the
BDES (Table 5). We detected similar covariate effects using
additive models. We have listed these covariate models and
their effects for the FARMS data set in Table 6. The additive
models E2E3Add and E3E4Add showed results similar to
those of the E3Add model.
DISCUSSION
The most significant finding was detected on chromosome
19 (at q13.21) with size in both the BDES and the FARMS.
Because this region was concordant in both studies, we
FIGURE 1. Multipoint results of the
genome-wide linkage analysis for size
and type in the BDES. For each chro-
mosome, genetic distance (in centi-
morgans) is plotted on the x-axis
against log10P on the y-axis.
FIGURE 2. Multipoint results of the
genome-wide linkage analysis for size
and type in the FARMS. For each
chromosome, genetic distance (in
centimorgans) is plotted on the x-
axis against log10P on the y-axis.
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propose that this can be considered as a replication. After
combining the probabilities, our result on chromosome 19
was more significant in aggregate (P  0.0005) than when
individually considered (P  0.0013 in FARMS and P 
0.0243 in BDES).
The APOE gene, mapped on 19q13.2, is an intriguing can-
didate gene residing close to the chromosome 19 linkage
signal. Numerous association studies of this gene have con-
firmed the association between APOE alleles and AMD.7,8,19–21
We have revealed evidence of linkage at that location using a
genome scan, whereas others have not done so.23,24,31–36 This
may be because most previous genome-wide linkage studies,
including ours,23,24 have focused on the late stages of disease
with AMD affection status, as opposed to focusing on the early
stages of the disease. We were able to find some APOE gene
involvement on large drusen presence, although our results
suggest that a novel locus for drusen formation might reside
close to the APOE locus. Thus, it may be necessary to examine
this chromosomal region more carefully for other genes in
linkage disequilibrium with APOE.
At the linkage signal on 14q32.33, we did not find known
genes that might be involved in AMD or drusen. However,
the Usher syndrome type 1A gene (USH1A; 14q32) maps
near this region.37,38 For the region on 21q21.2, amyloid
beta A4 precursor protein (APP; 21q21) is considered as an
interesting candidate gene. In a recent study,39 a macromo-
lecular assembly was observed that contains amyloid  as
well as activated complement components in drusen, sug-
gesting that some of the pathogenic pathways that give rise
to drusen and AMD may be shared with other neurodegen-
erative diseases.
Our results on 3p24.3, 5q33.3, and 16p13.13 are consistent
with those reported in previous genome scans with AMD
phenotypes. Using size and type of drusen, we were able to
confirm the linkage signals on both arms of chromosomes 3
found in our previous BDES genome scan,23 where the 15-scale
AMD severity score used included drusen phenotypes as a
semiquantitative trait. TIMP4, the tissue inhibitor of metallo-
proteinase mapped on 3p25 could be a potential candidate
gene, because TIMP4 immunoreactivity was detected in situ
from human RPE choroids.40 A chemokine receptor (CCR2) on
3p21 could also be considered as a candidate gene, because
ccl2 or ccr2 aged knockout mice exhibit cardinal features of
AMD, including accumulation of lipofuscin and drusen beneath
the RPE, photoreceptor atrophy, and choroidal neovasculariza-
tion.41
Our finding of linkage on chromosome 5 agrees with the
result of our previous genome scan,24 but the shape of the
signal is refined with drusen size as the phenotype (Fig. 2). This
region was also identified by a genome scan,34 using ARM
TABLE 2. Multipoint P-Values in the BDES and the FARMS on Chromosomes 5, 14, 16, 19, and 21 for









Chromosome 5: Chromosome 5:
158.0 0.0043 D5S820 (159.68) 0.8895
D5S820 (160.0) 0.0021 160.0 0.8826
162.0 0.0023 162.0 0.8208
164.0 0.0032 164.0 0.7142
166.0 0.0060 166.0 0.5629
168.0 0.0146 168.0 0.4024
170.0 0.0383 170.0 0.2753









Chromosome 19: Chromosome 19:
38.0 0.0290 D19S433 (34.0) 0.2288
40.0 0.0076 36.0 0.1838
D19S433 (42.0) 0.0025 38.0 0.1455
44.0 0.0016 40.0 0.1177
46.0 0.0013 D19S245 (42.0) 0.0995
48.0 0.0016 44.0 0.0616
D19S245 (49.0) 0.0019 46.0 0.0393
50.0 0.0023 48.0 0.0287
52.0 0.0045 D19S178 (50.0) 0.0243
54.0 0.0117 52.0 0.0326
56.0 0.0323 54.0 0.0497
Type Type
Chromosome 21: Chromosome 21:
D21S2052 (22.0) 0.0070 22.0 0.3441
24.0 0.0096 24.0 0.3603
* Markers are not in this screening set.
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affection status, and also showed a bifurcation in the shape of
the linkage signal in this region. The authors suggested gluta-
thione peroxidase 3 (GPX3; 5q33.1) as a potential candidate
gene.
A recent genome scan showed linkage on 16p using AMD
affection status and ordered subset analysis.42 This region har-
bors MMP25 on 16p13.3, a type of matrix metalloproteinase
protein similar in function to MMP3 on 11q23. This is likely to
be a good candidate gene because the pattern of MMP immu-
noreactivity was detected only on the surface of drusen, but
was absent in the central part of drusen, implying that drusen
are regions lacking proteolysis activity.40
Our approach differs from other previous genome-wide
linkage studies for AMD or ARM in two respects. First, we have
isolated drusen phenotypes from the AMD trait, to investigate
the relationship between AMD and drusen phenotypes. Fur-
thermore, we categorized size and type, adapting the scale of
severity to cover a wide range of clinical phenotypes, and used
them as quantitative traits to provide greater power to detect
linkage. Second, we conducted linkage analyses on two inde-
pendent data sets. As a result, the finding of one analysis not
only acts as a replicate to the other, but also as a reference to
investigate the similarity and difference of pattern and location
of a linkage signal.
Although there are various criteria to characterize drusen
phenotypes, we defined the severity of the disease pheno-
type by maximum involvement of type and size based on the
natural progression of drusen in ARM. Only some progress
from small, hard (HD) drusen to soft distinct (SD) drusen
and even less progress to soft indistinct (SI) drusen. We used
this approach deliberately, because in these analyses we are
looking for the most severe phenotype, not the presence of
a specific type of drusen, knowing that approximately 90%
or more of subjects have at least one HD in one eye. There-
fore, if we use a criterion that includes HD, we would end
up with HD only, HD and SD, and HD and SI, as well as HD,
SD, and SI. We believe this would give less chance to
TABLE 3. Multipoint P-Value for Drusen Size and Type in the BDES on Chromosomes 3 and 19, Where






Chromosome 3: Chromosome 3:
46.0 0.0485 46.0 0.0555
48.0 0.0408 48.0 0.0617
50.0 0.0377 50.0 0.0714
52.0 0.0372 52.0 0.0826
D3S2432 (52.38) 0.0373 D3S2432 (52.38) 0.0847
54.0 0.0289 54.0 0.0458
D3S1768 (55.98) 0.0264 D3S1768 (55.98) 0.0240
56.0 0.0265 56.0 0.0240
58.0 0.0327 58.0 0.0200
60.0 0.0482 60.0 0.0189
62.0 0.0816 62.0 0.0221
64.0 0.1442 64.0 0.0316
D3S2409 (65.07) 0.1882 D3S2409 (65.07) 0.0396
66.0 0.2016 66.0 0.0483
158.0 0.3080 158.0 0.0332
160.0 0.2282 160.0 0.0221
D3S1299 (161.39) 0.1970 D3S1299 (161.39) 0.0209
162.0 0.1658 162.0 0.0181
164.0 0.1008 164.0 0.0175
D3S1746 (164.06) 0.0997 D3S1746 (164.06) 0.0177
166.0 0.1777 166.0 0.0141
D3S2404 (166.73) 0.1353 D3S2404 (166.73) 0.0176
168.0 0.1626 168.0 0.0238
170.0 0.2228 170.0 0.0453
Chromosome 19: Chromosome 19:
D19S245 (42.0) 0.0995 D19S245 (42.0) 0.1538
44.0 0.0616 44.0 0.1020
46.0 0.0393 46.0 0.0684
48.0 0.0287 48.0 0.0508
D19S178 (50.0) 0.0243 D19S178 (50.0) 0.0429
52.0 0.0326 52.0 0.0765








2/2 0 (0.00%) 0 (0.00%)
2/3 46 (14.15%) 44 (15.17%)
2/4 1 (0.31%) 6 (2.07%)
3/3 193 (59.38%) 158 (54.48%)
3/4 71 (21.85%) 65 (22.41%)
4/4 9 (2.77%) 6 (2.07%)
Missing 5 (1.54%) 11 (3.79%)
APOE allele
2 47 (7.23%) 50 (8.62%)
3 503 (77.38%) 425 (73.28%)
4 90 (13.85%) 83 (14.31%)
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identify disease susceptibility genes for large soft drusen,
which are known to be associated with progression to more
advanced AMD. Analyzing drusen area within the central
macula is an alternative approach, since the extent of the
macular area covered by drusen correlates highly with size
and type. In our previous analyses,23,24 we used drusen area
as the least-severe steps of our AMD score. Comparing our
current results with the previous results should further
refine the relationship between AMD and the drusen phe-
notypes as defined by our group.
In view of our findings from covariate analysis for the
APOE gene, we cannot definitively conclude that this gene is
the source of the linkage signal on chromosome 19. Equally,
we cannot rule out the possibility that linkage methods to
identify variants with low to moderate effect sizes (e.g.,
APOE alleles) may not have sufficient power in family-based
studies. We also observed that the two phenotypes, size and
type, correlated highly in both the BDES and the FARMS (see
the Methods section). However, for type, we failed to pro-
vide evidence of linkage on chromosome 19 in the FARMS.
In contrast, we observed a weak linkage peak in the BDES.
This may be because the number of individuals with soft
drusen was smaller in the FARMS than in the BDES (Table 1),
and consequently the effect size may not be big enough.
Alternatively, the genes present in individuals with end-
stage disease, as applicable to the FARMS, are unique. These
two hypotheses are equally supported by the fact that the
correlation between drusen phenotypes and the AMD score
(see the result section) was higher in the BDES than in the
FARMS.
When we tested the AMD score as a covariate to understand
the relationship between the drusen phenotypes and AMD
phenotype for the observed linkage on chromosome 19, inclu-
sion of the AMD score did not modify the linkage results at the
marker D19S245 (baseline: P  0.0016, with covariate: P 
0.0013) in the FARMS, or at the marker D19S178 (baseline:
P  0.0377, with covariate: P  0.0293) in the BDES. This
supports our hypothesis that among linkage regions for the
drusen phenotypes a few may be independently acting on the
AMD pathogenesis, and the region on chromosome 19 may be
one of them.
In summary, our evidence of linkage on chromosomes 14
and 19 suggest that specific loci for drusen formation, in
particular drusen size, are present. These data imply that
APOE and other novel loci are associated with large drusen.
Similarly, the region on chromosome 21 may be linked to
the type of drusen. These regions may be exclusively in-
volved in drusen formation, because no genome scans have
identified these regions for ARM or AMD. In contrast, the
loci on chromosomes 3, 5, and 16 confirmed published
genome-wide linkage reports for ARM or AMD. Thus, our
results, together with other previous findings, have pro-
vided better insights into the intertwined nature of multiple
genetic influences on AMD, implying that different genes act
at different stages of the disease, which contribute sepa-
rately or together to the final AMD disease outcome. In the
TABLE 5. Multipoint Model-Free Linkage Analysis of Drusen Size in the BDES and FARMS Including APOE Alleles as a Covariate
in the Regression
FARMS BDES
Location —* E3Dom† E4Dom Location —* E3Dom† E4Dom
38.0 0.0356 0.0229 0.0385 D19S433 0.2478 0.2423 0.2362
40.0 0.0169 0.0062 0.0111 36.0 0.1993 0.1944 0.1854
D19S433 0.0098 0.0022 0.0041 38.0 0.1573 0.1533 0.1421
44.0 0.0057 0.0020 0.0039 40.0 0.1265 0.1232 0.1109
46.0 0.0041 0.0026 0.0049 D19S245 0.1059 0.1034 0.0907
48.0 0.0040 0.0045 0.0082 44.0 0.0655 0.0644 0.0560
D19S245 0.0044 0.0064 0.0111 46.0 0.0415 0.0412 0.0361
50.0 0.0053 0.0069 0.0125 48.0 0.0299 0.0300 0.0267
52.0 0.0101 0.0099 0.0192 D19S178 0.0250 0.0254 0.0230
54.0 0.0248 0.0180 0.0351 52.0 0.0336 0.0342 0.0299
56.0 0.0617 0.0353 0.0664 54.0 0.0513 0.0525 0.0442
* The baseline model with no covariate is shown.
† In the dominant model the presence of the specific allele in a genotype is coded as 1; its absence is coded as 0.
TABLE 6. Extended Covariate Analysis for Drusen Size in the FARMS, Using Model-Free Multipoint Linkage Analysis of the Candidate Region on
Chromosome 19
Location — E3Dom E4Dom E2Dom* E3Add† E4Add
38.0 0.0356 0.0229 0.0385 0.0277 0.0275 0.0329
40.0 0.0169 0.0062 0.0111 0.0078 0.0076 0.0095
D19S433 0.0098 0.0022 0.0041 0.0028 0.0075 0.0035
44.0 0.0057 0.0020 0.0039 0.0027 0.0058 0.0034
46.0 0.0041 0.0026 0.0049 0.0035 0.0032 0.0045
48.0 0.0040 0.0045 0.0082 0.0059 0.0057 0.0077
D19S245 0.0044 0.0064 0.0111 0.0082 0.0079 0.0106
50.0 0.0053 0.0069 0.0125 0.0091 0.0087 0.0118
52.0 0.0101 0.0099 0.0192 0.0133 0.0128 0.0174
54.0 0.0248 0.0180 0.0351 0.0242 0.0232 0.0314
56.0 0.0617 0.0353 0.0664 0.0471 0.0447 0.0590
* In the dataset, there are no 2/2 homozygous genotypes.
† In the additive model the covariate is the number of a specific allele in a genotype.
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future, we hope to investigate several different aspects of
AMD and its progression, providing new perspectives for
the underlying genetic mechanism of AMD.
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